This article is being processed. Please check back shortly.
Share this article
Analysis
Neutral
Sanofi’s lunsekimig hits primary and key secondary endpoints in phase 2 Asthma and CRSwNP trials
Apr 07, 2026 07:26 UTC
Stay Ahead of the Markets
Join thousands of traders using AI-powered market intelligence. Get personalized insights, real-time alerts, and advanced analysis tools.